Health Care Facilities

Aier

Aier released FY2026 Q1 earnings on April 23 During-Market (BJT), actual revenue CNY 6.396 B (forecast CNY 6.571 B), actual EPS CNY 0.1274 (forecast CNY 0.13)

Aier released FY2025 Q4 earnings on April 23 After-Market (BJT), actual revenue CNY 4.869 B (forecast CNY 4.945 B), actual EPS CNY 0.0134 (forecast CNY 0.0395)

Aier released FY2025 Annual Earnings on April 23 After-Market (BJT), actual revenue CNY 22.35 B (forecast CNY 22.59 B), actual EPS CNY 0.3496 (forecast CNY 0.392)

Aier to release FY2025 earnings on April 24 After-Market BJT, forecast revenue CNY 22.59 B, EPS CNY 0.392

Aier FY2026 Q1 Earnings Release on April 24 During-Market (BJT), Forecast Revenue CNY 6.571 B, EPS CNY 0.13

Aier released FY2025 Q3 earnings on October 27 Pre-Market (BJT), actual revenue CNY 5.977 B (forecast CNY 6.349 B), actual EPS CNY 0.1151 (forecast CNY 0.1444)

Aier released FY2025 9 Months Earnings on October 27 Pre-Market (BJT), actual revenue CNY 17.48 B, actual EPS CNY 0.337

Aier to release FY2025 Q3 earnings on October 28, pre-market (BJT), forecast revenue CNY 6.349 B, EPS CNY 0.1611

Aier released FY2025 Semi-Annual earnings on August 27 During-Market (BJT), actual revenue CNY 11.51 B, actual EPS CNY 0.2218

Aier released FY2025 Q2 earnings on August 27 During-Market BJT, actual revenue CNY 5.481 B (forecast CNY 5.687 B), actual EPS CNY 0.1083 (forecast CNY 0.1198)

Aier to release FY2025 Semi-Annual earnings report on August 27, 2025 (BJT)

Aier Eye Hospital and Huawei Sign AI Strategic Cooperation Agreement

Aier Eye Hospital Wholly Owns Shijiazhuang Aier Optometry Hospital

Eyenet First Quarter Revenue Growth Outpaces Stock Performance

Aier Eye Hospital and Meituan Health Launch 'Optimal Vision' Public Welfare Program

Aier Eye Hospital Chairman Chen Bang Clarifies No Immediate Plans for HK Listing

Aier Eye Hospital Acquired 60% Equity of Shenzhen Guangsheng Sci-Tech Tower for 650 Million Yuan

Shenzhen Binhai Aier Acquires 60% Equity and Specific Claims of Guangsheng Digital

Aier Eye Hospital Exempted from VAT on Medical Services

Aier Eye Care Registers New 'Aier Medical Cloud Platform 1.0' Software Copyright

300015

06622

02219

China's leading private ophthalmology hospital chain Aier Eye plans to go public in Hong Kong to enhance brand awareness and broaden financing channels. Despite facing intense competition and price pressure, the company hopes to achieve growth through the expansion of the international ophthalmology market. Last year, its overseas ophthalmology clinic revenue grew by approximately 16%, double the overall revenue growth rate

BambooWorks

ZHAOKE OPHTH-B

CHAOJU EYE CARE

Penghua SSE STAR Biology and Medicine ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Dacheng CSI All Share Health Care Equipment and Services ETF

ChinaAMC CSI Biotechnology Theme ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

China Merchants CSI Biotechnology Theme ETF

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

Bosera Hang Seng Health Care ETF(QDII)

E Fund CSI 300 Health Care ETF

ICBCCS SSE STAR Biology and Medicine ETF

Ping An CSI Medicine and Medical Device Innovation ETF

E Fund CSI Biotechnology Theme ETF

China Merchants CSI All Share Medical Apparatus and Instruments ETF

ChinaAMC CSI All Share Health Care Devices ETF

Guotai CSI Bio-medicine ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

ChinaAMC SSE STAR Biology and Medicine ETF

China Southern Hang Seng Biotech ETF(QDII)

C-MER MEDICAL

Looking for overseas growth, Aier Eye seeks Hong Kong listing

Aier Eye Hospital Group is pursuing a listing on the Hong Kong Stock Exchange to enhance its international presence and access capital, despite previously downplaying such plans. The company aims to shift market perceptions amid stiff competition and pricing pressures in China, where its revenue growth has slowed. Aier Eye's overseas income rose 16% last year, contributing to its expansion strategy. However, the Hong Kong market may offer lower valuations compared to mainland shares, posing potential risks for investors. The company's shares rose 5.57% following the board's decision to pursue the listing.

benzinga_article

Aier Eye Seeks Hong Kong Listing For International Growth

Aier's board of directors has approved the relevant proposal for listing in Hong Kong, which requires approval from the shareholders' meeting and regulatory authorities. The company's profit is expected to decline by 8.88% in 2025, but the net profit in the first quarter of 2023 rebounded to 1.181 billion yuan, a year-on-year increase of 12.46%. Overseas business has become a new highlight, with expected overseas revenue reaching 3.057 billion yuan in 2025, accounting for 13.68% of total revenue. This listing aims to broaden international financing channels, and management stated that this move is to address valuation pressure and seek new narratives in the capital market

Aier plans to go public in Hong Kong. Can overseas expansion support the new valuation of "eye king"?

After years of rapid expansion, the leader in the ophthalmology sector is facing the reality of diminishing scale effects. On April 24, Aier released its 20

Wallstreetcn

Breaking the Diminishing Returns of Scale: Aier Seeks Global Expansion via Hong Kong Listing

Aier reported first-quarter revenue of 6.4 billion yuan and net profit of 1.18 billion yuan. Full-year revenue reached 22.35 billion yuan against analyst expectations of 22.54 billion yuan, while full-year net profit came in at 3.24 billion yuan compared to the expected 3.64 billion yuan

Recently, there have been market rumors that Aier is planning to list in Hong Kong. In response, Aier has taken a relatively cautious stance, stating on the afternoon of March 17

Aier Eye Hospital is preparing for a listing in Hong Kong, expected to become the first "A+H" ophthalmology hospital

Aier Eye Hospital is planning to go public in Hong Kong, and related preparations are underway. The company stated that significant information should be subject to official announcements. Insiders have confirmed that the news is true. If successful, Aier Eye Hospital will become the first ophthalmology hospital to be listed in both A-share and H-share markets

Aier Eye Hospital plans to go public in Hong Kong and is indeed "ready to shoot."

Aier Eye Hospital Group, China's largest eye hospital chain, is planning a listing in Hong Kong, joining other mainland companies seeking to raise funds. The company is currently working with an adviser on the share sale, with discussions on offer size and timing ongoing. Aier, which trades in Shenzhen with a market cap of approximately 96 billion yuan, has seen its shares decline 26% over the past year. The Hong Kong market has experienced a resurgence in fundraising, particularly from Chinese tech firms and other companies looking to expand internationally.

Businesstimes News

American Shared Hosp

China’s biggest eye hospital chain Aier plans Hong Kong listing: sources

Aier is considering an IPO in Hong Kong and is working with advisors to prepare for it, with the specific scale and timing still under discussion. The company has a market capitalization of approximately 96 billion RMB, and its stock price is close to a five-year low, having fallen about 26% in the past 12 months. Aier was founded in 2002, and its medical network covers Asia, Europe, and North America, with a total of 976 hospitals and clinics worldwide, including 807 in mainland China and 9 in Hong Kong

AASTOCKS

According to reports, Aier is considering listing in Hong Kong

Aier Eye Hospital is reportedly planning to go public on the Hong Kong Stock Exchange. (Bloomberg)

Aier(300015.SZ)